A recurrent de novo missense variant in KCNC1, encoding a voltage-gated potassium channel expressed in inhibitory neurons, causes progressive myoclonus epilepsy and ataxia, and a nonsense variant is associated with intellectual disability. We identified three new de novo missense variants in KCNC1 in five unrelated individuals causing different phenotypes featuring either isolated nonprogressive myoclonus (p.Cys208Tyr), intellectual disability (p.Thr399Met), or epilepsy with myoclonic, absence and generalized tonic-clonic seizures, ataxia, and developmental delay (p.Ala421Val, three patients). Functional analyses demonstrated no measurable currents for all identified variants and dominantnegative effects for p.Thr399Met and p.Ala421Val predicting neuronal disinhibition as the underlying disease mechanism.
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Abstract
A recurrent de novo missense variant in KCNC1, encoding a voltage-gated potassium channel expressed in inhibitory neurons, causes progressive myoclonus epilepsy and ataxia, and a nonsense variant is associated with intellectual disability. We identified three new de novo missense variants in KCNC1 in five unrelated individuals causing different phenotypes featuring either isolated nonprogressive myoclonus (p.Cys208Tyr), intellectual disability (p.Thr399Met), or epilepsy with myoclonic, absence and generalized tonic-clonic seizures, ataxia, and developmental delay (p.Ala421Val, three patients). Functional analyses demonstrated no measurable currents for all identified variants and dominantnegative effects for p.Thr399Met and p.Ala421Val predicting neuronal disinhibition as the underlying disease mechanism. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction
Epilepsy and intellectual disability (ID) are common neuropsychiatric disorders with an approximate prevalence of 0.3 to 2%. [1] [2] [3] [4] A subgroup of cases is due to pathogenic variants in potassium channels, which, however, might also present with a range of additional neurological features, such as ataxia. [5] [6] [7] [8] [9] The potassium channel subfamily K V 3 consists of four subunits (K V 3.1, K V 3.2, K V 3.3, and K V 3.4) which are encoded by KCNC1, KCNC2, KCNC3, and KCNC4.
10 Mutations in KCNC3 are a well-established cause of spinocerebellar ataxia type 13, whereas KCNC2 and KCNC4 have so far not been associated with human disease. 8, 9 The evolutionarily highly conserved voltage-gated potassium channel K V 3.1 is predominantly expressed in fast-spiking neurons to enable high-frequency firing by fast channel activation and membrane repolarization. 10 Fast-spiking neurons include GABAergic interneurons in the neocortex and hippocampus, Purkinje cells in cerebellum, and neurons in central auditory nuclei. 10, 11 To date, only one recurrent de novo missense variant in KCNC1 (c.959G > A, p.Arg320His) has been reported as a cause of progressive myoclonus epilepsy and ataxia (MEAK; OMIM #616187). The respective phenotype is similar to Unverricht-Lundborg disease. [12] [13] [14] [15] Subsequently, one nonsense variant (c.1015C > T, p.Arg339*) has been identified in three affected members of single family with ID without seizures. 16 Here, we report three new pathogenic de novo missense variants in KCNC1 in five unrelated patients. The provided clinical information adds to the phenotypic delineation of KCNC1-related disease.
Patients, Materials, and Methods

Clinical and genetic investigations
Patients were evaluated by neurologists and referred for diagnostic whole exome sequencing (WES) at different centers. The methods for WES and Sanger sequencing have been previously described. 17, 18 Written informed consent to participate in this study was obtained from all patients or their parents.
Functional analysis
The functional evaluation of identified KCNC1 variants was performed using two-electrode voltage-clamp recordings as previously described. 13 Briefly, the three missense variants were introduced in the human KCNC1 cDNA (NM_004976) cloned in a pCMV Entry Vector (OriGene Technologies, USA) using the Quick Change Method (Stratagene, USA). The plasmids were linearized and in vitro transcription was performed using T7 RNA Polymerase (Roche Diagnostics GmbH, Germany). Xenopus laevis oocytes (EcoCyte Bioscience, Germany) were washed in OR2 and incubated in Barth solution with gentamycin. Fiftynanoliters of cRNA (2 µg/µL) was injected using Robooinjectâ (Multichannel Systems, Germany) and stored at 16°C. Potassium currents were recorded after 2-3 days at room temperature (21-23°C) on Roboocyte2â (Multichannel Systems, Germany). Data analysis and graphical illustrations were achieved using Roboocyte2+ (Multichannel Systems, Germany), Excel (Microsoft, USA), and Graphpad Software (GraphPad Software, USA). Statistical evaluation for multiple comparisons (P < 0.05) was conducted using one-way ANOVA on ranks with Dunn's post hoc test.
Results
Genetic testing
WES revealed three different heterozygous missense variants in KCNC1 (NM_001112741.1) in five unrelated patients. Patient 1 carries c.623G > A, p.Cys208Tyr, patient 2 c.1196C > T, p.Thr399Met, and patients 3, 4, and 5 c.1262C > T, p.Ala421Val. All variants are absent from public databases [1000 Genomes project, Genome Aggregation Database (gnomAD 2.0.2), Exome Aggregation Consortium (ExAC 0.3.1)]. In line with a postulated de novo status, none of the variants was detected in DNA extracted from parental whole blood (Fig. 1A) . Additional rare variants identified in patients 1, 2, and 3 are provided in Table S1 . We cannot entirely rule out a potential contribution of these changes to the observed phenotypes. However, to the best of our knowledge there is currently no evidence supporting a functional relevance and putative disease association of these additional changes.
Clinical phenotypes
Patient 1 (Cys208Tyr)
A 23-year-old German woman reported that mild tremorlike symptoms began on both hands at the age of 2 years.
Her psychomotor development was normal. Neurological examination revealed mild and nonprogressive constant high-frequency action and postural myoclonus (or irregular tremor) on both arms with dystonic features on the right hand and arm with constant hyperextension of the fourth and fifth finger and reduced arm swing during gait (Video S1). The patient initially received diagnostics and various treatments for tremor without success (see below), and the quite jerky aspect of the irregular movements is more reminiscent of myoclonus in our opinion. An electromyographical (EMG) recording which might have helped to distinguish between tremor and myoclonus has not been performed. Copper metabolism, F-dopa PET, and MRI scans of the brain and multiple EEG recordings were normal. Treatment trials with beta blockers, levodopa, and primidone were unsuccessful. Epileptic seizures were not reported.
Patient 2 (Thr399Met)
An 18-year-old German male works in a sheltered workshop and shows some articulation difficulties. When he was last examined at the age of 11 years, he was attending special school. He was diagnosed with mild to moderate intellectual disability and showed behavioral abnormalities, for example, difficulties socializing with other children. Motor development was slightly delayed, but his language was severely affected with first words by the age of 5 years. Dysmorphic features are shown in Figure 1D . There were neither congenital malformations nor any reported seizures. Neurological examination was unremarkable. EEG and MRI scan of the brain were normal.
Patient 3 (Ala421Val)
Patient 3 is a 5-year-old Croatian female in whom seizures (focal onset impaired awareness seizures, tonic-clonic and myoclonic seizures) were first noted at 5 months of age and occurred up to 40 times per day. First generalized tonic-clonic seizures started at the age of 2 years. Treatments with levetiracetam, zonisamide, and carbamazepine were unsuccessful. Finally, a combination therapy with clobazam and topiramate reduced her seizure frequency to 1-2 per month. She had global developmental delay and mild gait ataxia, which was so far nonprogressive. The EEG showed multifocal epileptic discharges and irregular spike-wave complexes with polyspikes followed by bilateral synchronic 2/s spike-wave activities. Cerebral MRI was normal.
Patient 4 (Ala421Val)
Patient 4, a 2-year-old female of Turkish origin, first presented with febrile seizures 3 weeks after birth. Seizures then occurred 15-35 times per day and lasted for 5-35 sec with even higher seizure frequencies during episodes with high fever, which did not respond to levetiracetam or valproate. She mostly had myoclonic absence seizures (Video S1), and less frequently myoclonic seizures without impaired awareness or absence seizures without myoclonus. During the myoclonic absence seizure, her eyes rolled upwards and both her proximal arms twitched for a few seconds. Her global development was delayed. She is now able to walk and vocalize but does not speak. Twenty-four-hour-EEG showed normal background activity and multiple seizure episodes with rhythmic bifrontal 2-3/s spike-wave discharges for 6-20 sec. Cerebral MRI was unremarkable (Fig. S2 ).
Patient 5 (Ala421Val)
This 2-year-old Chinese-French male showed first myoclonic seizures at 5 months of age. The initial seizure frequency was 1-2 per day, which increased to 60-70 per day after 4 months. Treatment with valproate, levetiracetam, and clonazepam reduced his seizure frequency dramatically to once per month. He had predominantly myoclonic absence seizures (Video S1 with face covered) presenting with rapid eyelid myoclonia accompanied by twitching of proximal arms. The myoclonus was mostly on the left side, but occasionally occurred on both arms. In addition, he also had absences without myoclonus lasting for approximately 10 sec. At 8 months, he had two generalized tonic-clonic seizures. The EEG showed episodes with generalized rhythmic discharges of 2-4 Hz, sometimes only as waves, sometimes as spike-waves, lasting up to 15 sec and often accompanied by myoclonic movements visible in the electromyographic trace (Fig. S3) . His development was delayed; he is now able to speak ten simple words, but cannot stand alone without any help. Cerebral MRI did not show any abnormalities.
Functional consequences of KCNC1 variants
Current amplitudes recorded in oocytes expressing either of the three mutant channels were barely detectable and similar to water-injected controls ( Fig. 2A and 2 ). Coexpression of wild type (WT) with mutant channels indicated dominant-negative loss-of-function effects with a significant decrease in K + current amplitudes of approximately 68% and 48% for Thr399Met and Ala421Val mutant channels compared to WT alone ( Fig. 2C and D) , whereas coexpression of Cys208Tyr mutant and WT channels did not cause a significant amplitude reduction. The activation curve showed a hyperpolarizing shift when WT channels were coexpressed with Ala421Val mutant channels in comparison to WT channels alone (Fig. 2E) , whereas Cys208Tyr channels did not show any significant difference. Thr399Met showed a strong dominant-negative effect on the WT which impeded the evaluation of further gating parameters.
Discussion
We here identified three new de novo missense variants in KCNC1 in five unrelated individuals presenting with different clinical phenotypes compared to previously reported KCNC1 patients. Patient 1 (Cys208Tyr) exhibited nonprogressive, relatively mild, action-induced myoclonus (or irregular tremor) as the only clinical sign without any cerebellar, epileptic, or cognitive symptoms. In contrast, MEAK patients (Arg320His) had a more severe and progressive action-induced myoclonus, epilepsy, and ataxia leading to wheelchair dependency in 11 of 22 published patients by the age of approximately 17 years. [13] [14] [15] The phenotype of patient 2 (Thr399Met), who showed ID and dysmorphic features, is more similar to the family reported by Poirier et al. in which three affected members carried the nonsense mutation Arg339*. 16 All three had similar dysmorphic features, which however differed from those observed in patient 2 (Fig. 1D, Table 1 ). Compared to MEAK patients, also the three unrelated patients (3, 4, and 5) carrying the Ala421-Val variant presented with different symptoms, neither showing myoclonus, but myoclonic and absence seizures and developmental delay. The presence of ataxia is difficult to judge as all three are still very young. While this study was underway, the change Ala421Val has been submitted to ClinVar by another group, indicating that it might represent a more frequent recurrent cause of ID and seizures. 19 Functional studies demonstrated a complete loss-offunction for all three variants with a significant dominant-negative effect on WT channels for Thr399Met and Ala421Val ( Fig. 2A-D) . Similar to the previously published variant Arg320His, Ala421Val caused a hyperpolarizing shift of the activation curve when coexpressed with WT, which was not observed for Cys208Tyr (Fig. 2E) . 13 In contrast to the haploinsufficiency of the truncating variant in the previously described family with ID, the variant Thr399Met, also causing ID alone, showed a pronounced dominant-negative effect. 16 Our current data do thus not reveal a clear correlation between the electrophysiological properties of mutant channels and clinical phenotypes. It is striking, however, that both recurring variants (Arg320His and Ala421Val) cause a different but homogeneous phenotype each, indicating specific effects of the variants themselves, despite their similar biophysical properties. Further functional characterizations in neuronal cells are needed to shed more light on the cellular and network mechanisms underlying the pathological effect of the variants on the nervous system. K V 3.1 is prominently expressed in inhibitory GABAergic interneurons in which these channels enable high-frequency firing by a rapid membrane repolarization. 10 The identified variants thus probably lead to impaired firing of GABAergic interneurons predicting neuronal disinhibition as the underlying disease mechanism. Patients 3 and 5 were both treated with benzodiazepines. Their effect on GABA neurotransmitters, enhancing the inhibitory effect on neurons might have played a critical role in reducing the patients' seizure frequencies. Also Oliver et al described that clonazepam beside valproate was most effective in MEAK patients.
14 Another more specific therapeutic strategy might be to directly activate mutant heterotetrameric K V 3 channels. The feasibility of such an approach with a compound called RE01 has been recently reported in vitro. 20 In conclusion, we provide evidence that de novo variants in KCNC1 cause more diverse phenotypes than described so far, such as nonprogressive myoclonus (or tremor) alone, intellectual disability, or epilepsy with myoclonic, absence and generalized tonic-clonic seizures with developmental delay.
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